La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Lupin Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Lupin ha un patrimonio netto totale di ₹143.7B e un debito totale di ₹29.2B, che porta il suo rapporto debito/patrimonio netto a 20.3%. Le sue attività totali e le sue passività totali sono rispettivamente ₹240.0B e ₹96.2B. L'EBIT di Lupin è ₹31.9B rendendo il suo rapporto di copertura degli interessi 17.1. Ha liquidità e investimenti a breve termine pari a ₹20.3B.

Informazioni chiave

20.3%

Rapporto debito/patrimonio netto

₹29.22b

Debito

Indice di copertura degli interessi	17.1x
Contanti	₹20.35b
Patrimonio netto	₹143.73b
Totale passività	₹96.24b
Totale attività	₹239.97b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Sep 17

Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 09

Unpleasant Surprises Could Be In Store For Lupin Limited's (NSE:LUPIN) Shares

Aug 01

Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jul 13

Lupin's (NSE:LUPIN) Dividend Will Be Increased To ₹8.00

Jul 12

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Jun 15

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

May 09

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

May 08

Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking

Apr 20

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 03

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Jan 19

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Nov 10

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Jun 23

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 24

Lupin's (NSE:LUPIN) Dividend Is Being Reduced To ₹4.00

Jul 08

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ₹134.5B ) di LUPIN superano le sue passività a breve termine ( ₹85.0B ).

Passività a lungo termine: Le attività a breve termine di LUPIN ( ₹134.5B ) superano le sue passività a lungo termine ( ₹11.2B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 6.2% ) di LUPIN è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di LUPIN si è ridotto da 61.6% a 20.3% negli ultimi 5 anni.

Copertura del debito: Il debito di LUPIN è ben coperto dal flusso di cassa operativo ( 124.9% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di LUPIN sono ben coperti dall'EBIT ( 17.1 x copertura).

Lupin Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Recent updates

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Price target increased by 12% to ₹1,835

Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Lupin Limited Announces Change of Company Secretary and Compliance Officer

Lupin Limited Approves Dividend for Year Ended March 31, 2024

Unpleasant Surprises Could Be In Store For Lupin Limited's (NSE:LUPIN) Shares

Lupin Limited to Report Q1, 2025 Results on Aug 06, 2024

Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Lupin's (NSE:LUPIN) Dividend Will Be Increased To ₹8.00

Full year 2024 earnings: EPS misses analyst expectations

Dividend increased to ₹8.00

Lupin Limited, Annual General Meeting, Aug 02, 2024

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Lupin Limited Announces Board Appointments

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

New minor risk - Dividend sustainability

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Full year 2024 earnings: EPS misses analyst expectations

Lupin Limited to Report Q4, 2024 Results on May 06, 2024

Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking

Lupin Limited Announces Change in Management

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.075% in the United States

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 12% to ₹1,355

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%

Insufficient new directors

Lupin Limited to Report Q3, 2024 Results on Feb 07, 2024

Lupin Receives Approval from U.S. FDA for Febuxostat Tablets

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.07% in the United States

Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.2%

Lupin Limited Receives Tentative Approval from U.S. FDA for Canagliflozin Tablets

Lupin Limited Launches First Fixed-Dose Triple Combination Drug, Vilfuro-G® for COPD Management in India

Lupin Limited Receives Tentative Approval from U.S. FDA for Dapagliflozin Tablets

Price target increased by 8.2% to ₹1,067

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited to Report Q2, 2024 Results on Nov 08, 2023

Lupin Limited Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution

Lupin Limited (BSE:500257) completed the acquisition of Ondero and Ondero - Met from Boehringer Ingelheim International GmbH.

Price target increased by 15% to ₹878

Lupin Limited Approves Dividend for the Year Ended March 31, 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Lupin Limited Receives Tentative Approval from U.S. Fda for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility

Upcoming dividend of ₹4.00 per share at 0.4% yield

Lupin Limited, Annual General Meeting, Aug 03, 2023

Lupin Limited Receives Approval from U.S. Fda for Cyanocobalamin Nasal Spray

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Lupin Limited Launches Thiamine Hydrochloride Injection USP in the United States

Lupin Launches Darunavir Tablets in the United States

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Third quarter 2023 earnings: Revenues in line with analyst expectations

Lupin Receives Approval from US FDA for Glycopyrrolate Injection, USP

Lupin Limited Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets

Lupin Limited to Report Q3, 2023 Results on Feb 09, 2023

Lupin Limited Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients

Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla in Spain for the Symptomatic Treatment of Myotonia in Adults with Non-Dystrophic Myotonic Disorders

Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets

Lupin Limited Launches Novel Fixed-Dose Triple Drug Combination Difizma® Dpi to Treat Inadequately Controlled Asthma

Lupin Limited Announces Christine Mundkur Steps Down from Board of Directors, Effective January 1, 2023

Lupin Launches Rufinamide Tablets USP in the United States

Lupin Launches Formoterol Fumarate Inhalation Solution in the United States

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind